Participated · Series B · Jul 2026

Transcripta Bio operates a closed-loop discovery engine that uses transcriptomic signature matching to find drug candidates whose molecular signatures invert patient-derived disease signatures. Its platform comprises a Disease Signature Atlas built from patient single-cell RNA sequencing data, a Drug-Gene Atlas mapping transcriptomic responses of compounds, and Conductor AI, a machine learning system trained on more than one billion gene responses. The company’s pipeline spans four programs across Myotonic Dystrophy, Facioscapulohumeral Muscular Dystrophy (FSHD), Autism Spectrum Disorder (ASD), and Huntington’s Disease (HD). Transcripta is advancing IND-enabling studies and preparing clinical work for its ASD and FSHD programs. The company is based in Palo Alto, California. It has raised $24 million since its Series A to accelerate progression of its pipeline toward human clinical trials.

Participated · Series A · Jun 2026

Syntax Bio develops a CRISPR-based Cellgorithm™ platform intended to program and accelerate stem cell differentiation to enable scalable cell therapies. The company is advancing a pancreatic beta cell therapy candidate for type 1 diabetes and plans to fund preclinical proof-of-concept studies with proceeds from its expanded Series A. Syntax Bio has publicly reported a collaboration with Mayo Clinic, received a grant from Breakthrough T1D, and published peer-reviewed research in Science Advances describing its technology. Financially, the company expanded its Series A to $14.4 million, bringing total funding to over $25 million. Leadership changes accompanying the financing include a CEO who joined in 2025 and new executive, board, and scientific advisory appointments to support translational development and commercialization. The company positions its platform as a way to replace slow, labor-intensive differentiation processes with a programmable approach to generate functional cells at scale.

Participated · Equity · May 2026

Techcyte provides a unified, AI-powered digital pathology platform that streamlines complex workflows, integrates with core lab systems, and enhances communication across the lab. The company partners with laboratories, scanner manufacturers, diagnostic hardware providers, and AI developers to deliver its platform to labs and clinics globally. Techcyte's veterinary business is currently profitable, and the company expects its environmental and human segments to reach profitability by next year. It is led by CEO Ben Cahoon and is headquartered in Orem, Utah. Techcyte announced it will deploy the newly raised capital to execute strategic priorities and support its path to profitability. The articles do not disclose revenue, user counts, or prior funding amounts.

Participated · Seed · Apr 2026

ViewsML develops an AI-driven virtual biomarker staining platform that virtualizes immunohistochemistry to deliver per-cell spatial biomarker insights from standard H&E slides. The platform is intended to preserve scarce tissue samples while accelerating research, clinical trials, and patient care. ViewsML is building a virtual biomarker library comprised of AI models that extract biomarker information directly from routine pathology images. The company has established strategic collaborations with healthcare institutions, diagnostic companies, and biopharma organizations to drive adoption across research and clinical applications. Led by CEO Kenneth To, ViewsML plans to use newly raised seed capital to commercialize the platform, expand partnerships, advance clinical validation of its virtual biomarker panels, and grow its engineering, scientific, and commercial teams.

Participated · Seed · Mar 2026

Sub-Q Bionics is developing a next-generation implantable lymphatic drainage system—described as bionic lymph node technology—intended to manage lymphedema by assisting lymphatic circulation beneath the skin. The technology is founded on scientific innovations from the Weizmann Institute of Science and Shamir Medical Center, and Yeda supported the company through its WIN venture creation platform. The company is headquartered in Stillwater, Minnesota. Its intended system aims to provide automatic fluid management and reduce symptoms such as pain, swelling, and mobility limitations for patients living with lymphedema. Sub-Q Bionics recently closed a $1.5 million pre-seed round to advance development toward pre-clinical milestones and to build regulatory and commercial plans. The company expects to open a seed round in Q2 2026.